Replies to post #20852 on DD Support Board and Research Team

[samsamsamiam]

Smallcapfortunes.com/Shawn Ambrosino/ CRGE

http://sunshine-for-seniors.blogspot.com/2010/06/po-box-243805-boynton-beach-florida.html

http://www.smallcapfortunes.com/clenergen-3-29/index.html.

Wednesday, June 16, 2010
CRGE.OBB: Pump and dump?
My father decended into dementia over a period of years. In this process, he got taken advantage of by every mail con available. Two years after taking care of his affairs and switching his mailing address to ours, he still receives mail for miracle cures, hot stock investments, etc., -- the same types of cons that wiped out his savings.

Therefore, I am starting this blog to inform any and all of some of these cons so that you can be on the alert for some of these in case your mother or father is getting these in the mail.

I am in the financial field, so the stock "tips" are particularly irratating. Today's "hot stock" tip comes from "M3 Profit Accelerator," which is signed by "Shawn Ambrosino" who claims to be an analyst. You can find the Internet equivalent at www.smallcapfortunes.com/clenergen-3-29/index.html.

The stock that they are promoting is Clenergen Corp (CRGE) [formerly American Bonanza Resources]. Now the first clue that something is amiss is that they provide the ticker, but not the extension that indicates that it is on the OTC Bulletin Board. If you check this company out at the SEC web site, www.sec.gov, you will see that company has no revenues, minor expenses, and no cash flow. In its form as American Bonanza Resources, it appeared to be a company without any activity. CRGE shows some signs of life (mostly through a recent recapitalization), but at www.sec.gov you will see that it is late in its required financial filing for this fiscal period.

The brochure has lots of facts and figures, but nothing concrete about the company. Hype and no substance. Classic.

You can subscribe to their newletter for $2,395 for two years. What a deal. The authors are also experts on lots of other subjects. Trinity Investment Research, incorporated in Florida (which is a giveaway because FL provides cloaking), is at the same address [103 NE 4th St. Delray Beach FL] (and owners) as 32 other companies, including Best Life Herbals, Natures Perfection, and Premier Turf. There is no evidence that any of the parties to these 32 companies (the threesome: Kyle Hodges, Alison Kacurov, and Brian Sodi) have financial experience or financial education. None show up at FINRA.org.

Shawn Ambrosino claims to be an analyst. If you check him out on the website for one of the "associated" newsletters, www.bestlife-herbals/about/, you will see that he claims to have been a professional wrestler and now edits a health magazine.

The company involved recently with CRGE's unregistered securities is Vastani Trading Company, which is a company incorporated in Germany. Ownership of the company is not clear.

The CEO of the Florida subsidiary of CRGE, is Robert D. Kohn [6165 NW 123rd, Coral Springs, FL], who is also listed on a large number of other businesses incorporated in Florida. These business are not necessarily in the same line of business as CRGE.

The stock of CRGE.OBB is trading around 93 cents per share. If you go to finance.google.com or finance.yahoo.com and check out the trading, you will see the spikes in the price (as high as $1.20) when they ship these newsletters out.

Financial facts about CRGE:
Year end Oct 2009
Revenues = $0
General, selling and administrative expenses = $1.072 million
Research and development = $0
Net loss = -$1.072 million
Total assets = $63 thousand
Shareholders' equity = -$488 thousand
Cash flow from operations = -$899 thousand

Be careful out there. If a company does not have revenues and a company that purports to be doing research has no R&D, there is no reason to get into the stock. Think you want to play the pump and dump and can figure out when to get in or out? Think again -- the market maker(s) for the stock control all.

Some further clues. Check out the disclaimer at www.bestpennystockbroker.com (bold added):
"IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of The M3 Profit Accelerator does not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by The M3 Profit Accelerator or an offer or solicitation to buy or sell any security. Enhance Skin Products, (EHSK), the company featured in this issue, appears as paid advertising, paid by Medford Financial Ltd to provide public awareness for EHSK. Medford Financial Ltd has approved and signed off as “approved for public dissemination” all statements made herein regarding EHSK’s history, assets, technologies, current as well as prospective business operations and industry information. The M3 Profit Accelerator and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from The M3 Profit Accelerator about EHSK. Although the information contained in this advertisement is believed to be reliable, The M3 Profit Accelerator, its publisher (Trinity Investment Research) and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. The M3 Profit Accelerator is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $550,000 for this and other online advertising efforts and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. The M3 Profit Accelerator is paid $1500 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from Enhance Skin Product’s investor relations firm, or at the Enhance Skin Product’s website www.enhanceskinproducts.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like EHSK, advice to investors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, Enhance Skin Products notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc. "

The fine print is always important. Note that Capital Media, Trinity Publishing, and M3 Profit Accelerator are all run by the same folks.
Posted by More sunshine at 1:34 PM

[sunspotter]

Well, here's two names mentioned in your post - Mylews Norin and Agora - getting a letters from the Feds - but not the SEC as you might have thought, but rather FDA!

On the list of new warning letters that was issued today by FDA:


"January 10, 2012


WARNING LETTER


OVERNIGHT MAIL
RETURN RECEIPT REQUESTED


Myles Norin, CEO
Agora Publishing
14 West Mount Vernon Place
Baltimore, MD 21201


Re: CMS #210473


Dear Mr. Norin:

This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.northstarnutritionals.com in December 2011 and has determined that your products "PureImmune Plus" and "Healthy Aging" are promoted for conditions that cause the products to be drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)]. The therapeutic claims on your website establish that these products are drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of your products with these claims violates the Act. You can find the Act and its implementing regulations through links at FDA's home page at www.fda.gov1.

Examples of some of the claims observed on your website include:

On the webpage entitled, "PureImmune Plus":

• "If you could take one easy step to help prevent your greatest fear wouldn't you take it? Stop living in fear of CANCER"
• "If you're "in the know" you may already know that selenium [an ingredient in the product] is helping us turn the corner in cancer protection."
• "Key to protecting you against cancer's deadly tricks before they start ... Anyone of selenium's [an ingredient in the product] following weapons could explain a positive effect on cancer protection. Studies suggest that . .. it impacts genes that are linked to the progression of cancer"

Agora Publishing

• "[I]t's [Epicor®, an ingredient in the product] free radical--fighting powers may actually have some natural anti-inflammatory properties ...."

On the webpage titled, "Healthy Aging":

• "Keeping your blood sugar in balance helps slow glycation - sugar eating away at your nerve and sensory cells."
• "Alpha Lipoic Acid (ALA) [an ingredient in the product] ... Studies show it improves insulin sensitivity, making it easier for your blood sugar to stay stable."
• "Chromium. [an ingredient in the product] Not just for supporting healthy blood sugar, Chromium may also help maintain glucose tolerance ...."
• "They're saying it [green tea, an ingredient in this product] can improve cholesterol."
• "And the proanthocyanidins in Leucoselect® [an ingredient in the product] have been shown to help folks fend off all kinds of blood vessel problems --from peripheral venous insufficiency (a big cause of leg pain) to ...."

These products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are "new drugs" under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally marketed in the U.S. without prior approval from FDA as described in section 505(a)of the Act [21 U.S.C. § 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.

Furthermore, these products are misbranded within the meaning of section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] in that the labeling for these drugs fails to bear adequate directions for use. Because these products are intended for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners, adequate directions cannot be written for them so that a layperson can use them safely for their intended uses. The introduction of a misbranded drug into interstate commerce is a violation of section 301(a) of the Act [21 U.S.C.§331(a)].

This letter is not meant to be an all-inclusive list of violations in your products and their labeling. It is your responsibility to ensure that products marketed by your firm comply with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials for your products to ensure that the claims you make for your products do not cause them to violate the Act. You should take prompt action to correct the violations described above and prevent their future recurrence. Failure to promptly correct these violations may result in regulatory action without further notice, such as seizure and/or injunction

Please notify this office in writing within fifteen (15) working days from your receipt of this letter as to the specific steps you have taken to correct the violations noted above and to assure that similar violations do not occur. Your response should include any documentation necessary to show that correction has been achieved. If you cannot complete all corrections before you respond, please explain the reason for the delay and state the date by which the corrections will be completed.

Please send your reply to the attention of CDR Rochelle B. Young, Compliance Officer, Food and Drug Administration, 6000 Metro Drive, Suite 101, Baltimore, Maryland 21215. If you have any questions regarding any issue in this letter, please contact CDR Young at 410-779-5437.


Sincerely,

/S/
Evelyn Bonnin
District Director"
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm286652.htm


The plot, as they say, thickens.

Here's the website for North Star Nutritionals:

https://www.northstarnutritionals.com/

You'd never guess they were owned by Agora Publishing from their website. All very curious.